News & Events

AAPharmaSyn, AnchorBio Solutions, and TSRL Inc. are excited to announce the formation of A2 BioPharm Collaborative, a strategic partnership designed to streamline the drug discovery and development process from target identification through IND-enabling studies. By integrating complementary expertise in chemistry, biology, and preclinical development, A2 BioPharm Collaborative offers a unified solution for advancing early-stage drug candidates.

​

Through this collaboration, A2 BioPharm Collaborative provides a full suite of services including target discovery and validation, high-throughput screening (HTS) and triage, medicinal chemistry, structure-activity relationship (SAR) analysis, lead optimization, synthesis of validated hits, bioanalytical testing (HPLC, LC-MS/MS), formulation development, and comprehensive in vitro and in vivo PK/ADME and toxicology studies. This end-to-end offering reduces administrative burden and fosters scientific synergy across disciplines.

​

A2 BioPharm Collaborative brings together:

• AAPharmaSyn’s extensive capabilities in custom synthesis, lead optimization, process R&D, and specialty chemical sourcing.

• AnchorBio Solutions’ advanced biology-focused services for assay development, target validation, screening, biomarker development, and sample analysis.

• TSRL Inc.’s integrated preclinical CRO services including formulation development, PK/ADME and toxicology studies, and strategic consulting for regulatory and funding support.

​

Together, A2 BioPharm Collaborative delivers a cohesive, high-impact approach to accelerate the path from discovery to IND; tailored for startups, biotechs, and academic innovators seeking a collaborative, scientifically-driven partner.